Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 22

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 22
---
 “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d). The initial exercise price of each Series A Warrant is $1.32 per share of Common Stock. The Series A Warrants are exercisable only following stockholder approval and expire five (5) years thereafter. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the Series A Warrant. The Series A Warrant exercise price and the related number of shares of Common Stock issuable upon exercise are subject to a “reset” provision upon certain events and are subject to anti-dilution protection upon any subsequent transaction at a fixed price lower than the warrant exercise price then in effect, as more fully described in the Series A Warrant. The initial exercise price of each Series B Warrant is $1.98 per share of Common Stock or pursuant to an alternative cashless exercise option. The Series B Warrants are exercisable only following stockholder approval and expire two and one-half (2.5) years thereafter. The Series B Warrant exercise price and the related number of shares of Common Stock issuable upon exercise are subject to a “reset” provision upon certain events, as more fully described in the Series A Warrant, and the Series B Warrant alternative cashless exercise provision provides that the Series B Warrant can be exercised without further payment to the Company and for three times the number of shares of Common Stock then subject to the Series B Warrant. The terms of the Warrants require that the Company seek such approval as may be required by the rules and regulations of Nasdaq (the “Warrant Stockholder Approval”). Accordingly, we are seeking stockholder approval of the following:

| • | to consent rendering inapplicable clause (i) of the definition of the Floor Price contained in Section 1.11 of the Series A Warrants and Section 1.10 of the Series B Warrants; |

| • | to consent effecting the adjustment in the exercise price and number of Series A Warrant Shares following a Dilutive Issuance pursuant to Section 3.2 of the Series A Warrants; |

| • | to consent effecting the alternative cashless exercise provision pursuant to Section 2.3 of the Series B Warrants; |

| • | to consent effecting the adjustment of the exercise price and number of (i) Series A Warrant Shares pursuant to Section 3.3 of the Series A Warrants, and (ii) Series B W